Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gateway: ARO-ANG3 in Homozygous Familial Hypercholesterolemia
NCT05217667Phase 2Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 4
01
Overview
A Phase 2 trial of zodasiran in homozygous familial hypercholesterolemia (HoFH), sponsored by Arrowhead Pharmaceuticals. Started Apr 2022; status: terminated.
02
Drugs
zodasiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT05217667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217667.